Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutex Health Inc. filings document the reporting obligations of a healthcare services and operations company with hospital, population health management and real estate-related activities. Recent Form 8-K reports furnish operating and financial results, including revenue, hospital division performance, earnings measures and cash flow, and disclose other corporate events tied to registration statements and auditor consents.
Proxy and annual-meeting filings cover board elections, advisory executive compensation votes, auditor ratification, common stock voting results and related governance disclosures. These documents also frame the company's capital actions, including common stock repurchase authorizations, within its public-company reporting record.
Nutex Health, Inc. director Scott J. Saunders reported receiving an equity award in the form of restricted stock units. On July 14, 2025, he was granted 603 RSUs at a price of $0 per unit, each representing the right to receive one share of Nutex common stock upon vesting.
These RSUs vest 100% on July 14, 2026. If Saunders leaves the company without cause before that vesting date, the award will vest on a pro-rata basis according to the actual time he remained in service with the company.
Nutex Health, Inc. director Michael Lee Reed received an equity grant of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock with $0.001 par value upon vesting, for no cash exercise price.
The 603 RSUs are scheduled to vest 100% on July 14, 2026. If Reed leaves the company without cause before that date, the RSUs will vest on a pro-rata basis according to his actual time in service during the vesting period. After this grant, Reed beneficially owns 603 RSUs directly.
Nutex Health, Inc. director Cheryl Yvonne Grenas reported an equity award in the form of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock upon vesting. These RSUs vest 100% on July 14, 2026, with a provision that if she leaves the company without cause during the vesting period, the award will vest on a pro-rata basis based on her actual time in service.
Nutex Health director Frank E. Jaumot reported receiving a grant of 603 restricted stock units (RSUs) of Nutex Health, Inc. common stock. The RSUs were granted on July 14, 2025 at an exercise price of $0 and are held directly.
Each RSU represents the right to receive one share of Nutex Health common stock upon vesting. The grant vests 100% on July 14, 2026, with a provision for pro-rata vesting based on time served if Jaumot leaves the company without cause during the vesting period.
Nutex Health Inc. (NUTX) filed a current report to note that its independent auditor, Marcum LLP, has provided formal consent for its audit report to be used in existing registration statements. The consent, filed as Exhibit 23.1, covers Marcum’s report on Nutex Health’s consolidated balance sheet as of December 31, 2023, along with the related consolidated statements of operations, changes in equity and cash flows for the two-year period ended December 31, 2023. That audit report is included in Nutex Health’s Form 10-K/A filed on November 18, 2025. This is a routine step that allows Nutex to continue using its audited financial statements in connection with previously filed registration statements.
Nutex Health Inc. (NUTX) reported that it has released its financial and operating results for the third quarter ended September 30, 2025. The company announced these results on November 19, 2025 and made them available through a press release.
The press release is furnished as Exhibit 99.1 to this current report on Form 8-K, and is designated as furnished rather than filed under securities laws, meaning it is not automatically incorporated into other securities offerings or filings unless expressly stated.
Nutex Health Inc. reported a sharp turnaround for the quarter ended September 30, 2025, with total revenue of $267.8 million versus $78.8 million a year earlier and net income attributable to Nutex of $55.4 million compared with a loss of $8.8 million. The hospital division drove most of the growth, generating $260.2 million in quarterly revenue and $700.5 million for the first nine months, up from $199.4 million in the prior-year period, while population health revenue was stable.
For the first nine months of 2025, total revenue rose to $723.6 million from $222.3 million, and net income attributable to Nutex improved to $59.0 million from a loss of $9.5 million. Basic earnings per share were $8.27 for the quarter and $9.63 year-to-date. Cash and cash equivalents increased to $166.0 million from $40.6 million at December 31, 2024, supported by $177.7 million of net cash from operating activities. Results include substantial non-cash stock-based compensation of $119.6 million year-to-date, largely tied to obligations for under-construction and ramping hospitals, and growing arbitration-related accruals under the No Surprises Act.
Nutex Health Inc. reported that it has announced its financial and operating results for the second quarter ended June 30, 2025. The company is sharing these results through a press release dated November 18, 2025, which is furnished as Exhibit 99.1. The company states that this results information, including the exhibit, is being furnished rather than filed under securities laws and will only be incorporated into other documents if expressly stated there.
Nutex Health Inc. reports sharply higher results for the quarter ended June 30, 2025, with total revenue rising to $243.985 million from $76.082 million a year earlier, driven mainly by hospital division revenue of $236.302 million. Gross profit increased to $124.924 million, and operating income climbed to $33.679 million. However, heavy stock-based compensation of $78.747 million, largely tied to obligations for under-construction and ramping hospitals, led to a net loss attributable to Nutex of $17.697 million for the quarter, even though consolidated net income was $16.144 million due to substantial earnings allocated to noncontrolling interests. For the first six months of 2025, revenue reached $455.774 million and net income attributable to Nutex was $3.520 million, with cash and cash equivalents increasing to $96.733 million. The company also recorded $68.785 million of accrued arbitration expenses related to No Surprises Act reimbursement disputes and disclosed new legal challenges over stock issuance terms.
Nutex Health Inc. reported that it has released its financial and operating results for the first quarter ended March 31, 2025. The company announced these results on November 18, 2025 and made them available through a press release furnished as an exhibit to this report. The press release, dated November 14, 2025, is provided as Exhibit 99.1 and contains the detailed figures and operational updates for the quarter.
The company also clarified that the information in this results announcement, including the press release, is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.